Swedish Orphan Biovitrum AB (publ) (BIOVF)
OTCMKTS · Delayed Price · Currency is USD
33.30
0.00 (0.00%)
At close: Oct 6, 2025
BIOVF Revenue
Swedish Orphan Biovitrum AB had revenue of 6.18B SEK in the quarter ending June 30, 2025, with 13.47% growth. This brings the company's revenue in the last twelve months to 26.97B, up 13.75% year-over-year. In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B with 17.65% growth.
Revenue (ttm)
26.97B SEK
Revenue Growth
+13.75%
P/S Ratio
3.85
Revenue / Employee
14.93M SEK
Employees
1,806
Market Cap
10.92B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Jushi Holdings | 256.36M |
| Nuo Therapeutics | 1.95M |
Swedish Orphan Biovitrum AB News
- 21 days ago - KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - Seeking Alpha
- 21 days ago - Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome - Nasdaq
- 23 days ago - Swedish Orphan Biovitrum AB (Publ) (SWOBY) Discusses On NASP And Uncontrolled Gout Call (Transcript) - Seeking Alpha
- 24 days ago - Swedish Orphan Biovitrum AB (publ) - Special Call - Seeking Alpha
- 4 weeks ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 3 months ago - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Swedish Orphan Biovitrum AB (publ) 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Swedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue Growth - GuruFocus